Herpes zoster among persons living with HIV in the current antiretroviral therapy era

Journal of Acquired Immune Deficiency Syndromes

Volumn 61, Issue 2, 2012, Pages 203-207

  Blank, Leah J ^a   Polydefkis, Michael J ^a   Moore, Richard D ^a   Gebo, Kelly A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

age; ART; herpes zoster; HIV; shingles

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; FAMCICLOVIR; VALACICLOVIR;

ADULT; AGED; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; BACTERIAL SUPERINFECTION; CD4 LYMPHOCYTE COUNT; CONFUSION; CONTROLLED STUDY; DISEASE ASSOCIATION; EYE DISEASE; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MENINGOENCEPHALITIS; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RISK FACTOR; URBAN POPULATION; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; FEMALE; HERPES ZOSTER; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; RISK FACTORS; URBAN POPULATION; YOUNG ADULT;

EID: 84867010707     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318266cd3c     Document Type: Article

References (23)

1. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005; 352:2271-2284.
2. Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, et al. Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med. 2000;342:635-645.
3. Gebo KA, Kalyani R, Moore RD, et al. The incidence of, risk factors for, and sequelae of herpes zoster among HIV patients in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr. 2005; 40:169-174.
4. Veenstra J, Krol A, van Praag RM, et al. Herpes zoster, immunological deterioration and disease progression in HIV-1 infection. AIDS. 1995; 9:1153-1158.
5. Weller TH. Varicella and herpes zoster: a perspective and overview. J Infect Dis. 1992;166(suppl 1):S1-S6.
6. Buchbinder SP, Katz MH, Hessol NA, et al. Herpes zoster and human immunodeficiency virus infection. J Infect Dis. 1992;166:1153-1156.
7. Glesby MJ, Moore RD, Chaisson RE. Clinical spectrum of herpes zoster in adults infected with human immunodeficiency virus. Clin Infect Dis. 1995;21:370-375.
8. Glesby MJ, Hoover DR, Tan T, et al. Herpes zoster in women with and at risk for HIV: data from the women's interagency HIV study. J Acquir Immune Defic Syndr. 2004;37:1604-1609.
9. Song JY, Lee JS, Jung HW, et al. Herpes zoster among HIV-infected patients in the highly active antiretroviral therapy era: Korean HIV cohort study. J Acquir Immune Defic Syndr. 2010;53:417-418.
10. Moore RD. Understanding the clinical and economic outcomes of HIV therapy: the Johns Hopkins HIV clinical practice cohort. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17(suppl 1):S38-S41.
11. Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster. Pain. 1996;67:241-251.
12. Schneider E, Whitmore S, Glynn KM, et al. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged < 18 months and for HIV infection and AIDS among children aged 18 months to <13 years\United States, 2008. MMWR Recomm Rep. 2008;57(RR-10):1-12.
13. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)\a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377-381.
14. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med. 1965;58:9-20.
15. Rimland D, Moanna A. Increasing incidence of herpes zoster among veterans. Clin Infect Dis. 2010;50:1000-1005.
16. Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82:1341-1349.
17. Domingo P, Torres OH, Ris J, et al. Herpes zoster as an immune reconstitution disease after initiation of combination antiretroviral therapy in patients with human immunodeficiency virus type-1 infection. Am J Med. 2001;110:605-609.
18. Martinez E, Gatell J, Moran Y, et al. High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors. Clin Infect Dis. 1998;27:1510-1513.
19. Galil K, Choo PW, Donahue JG, et al. The sequelae of herpes zoster. Arch Intern Med. 1997;157:1209-1213.
20. Ragozzino MW, Melton LJ III, Kurland LT, et al. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore). 1982; 61:310-316.
21. Benson C, Hua L, Andersen J, et al. ZOSTAVAX is generally safe and immunogenic in HIV+ adults virologically suppressed on ART: results of a phase 2, randomized, double-blind, placebo-controlled trial. Presented at: Conference for Retroviruses and Opportunistic Infections; March 5-8, 2012; Seattle, WA. 2012:19.
22. Marin M, Guris D, Chaves SS, et al Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC). Prevention of varicella: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2007;56 (RR-4):1-40.
23. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1-30; quiz CE 2-4.